The second Self-Driving Laboratory (SDL) marks a shift from collaborative R&D toward potential full-scale deployment, using AI-guided experimentation and robotic automation to accelerate development timelines and cut chemistry research costs.

Pfizer executives say the SDL generates novel insights beyond simulations, speeds up development cycles, and the closed-loop architecture can be transferred to other domains needing rapid optimization of chemical or materials processes.

The installation underscores the strength of the Pfizer partnership, has the potential to compress development timelines, accelerate innovations to market, and extend the SDL’s applicability beyond pharmaceuticals to other sectors.

As a milestone, the installation signals a move toward full-scale deployment within Pfizer and highlights potential cost savings in drug development due to the collaboration.

The announcement notes ongoing market-scale expansion of SDL technology focused on cost savings, faster timelines, and broader deployment opportunities, while not disclosing specific revenue figures or timing.

Telescope Innovations positions its SDL as enabling faster, more efficient chemical manufacturing and experimentation for biopharmaceuticals, high-value specialty chemicals, and advanced materials to shorten time-to-market and reduce lab-to-market costs.

The SDL integrates collaborative robotics, real-time analytics (Process Analytical Technology), and machine-learning-guided experimental design in a fixed-position, closed-loop workflow capable of 24/7 autonomous operation across multiple vessels, potentially enabling up to 100x faster experimentation than traditional methods.

As a fixed-position Physical AI platform, the SDL runs autonomous, closed-loop experiments 24/7 across several vessels, dramatically increasing throughput and potentially reducing development timelines by up to 100 times compared with manual approaches.

Telescope Innovations completed installation of its second SDL at Pfizer in January 2026 under an existing multi-year agreement.

Pfizer’s second SDL installation, announced as completed in January 2026, advances the ongoing multi-year collaboration between Telescope Innovations and Pfizer.